on 15 Oct 2014
Last Applicant/ Owned by
Molecular Health GmbH
Kurfürsten-Anlage 21
Heidelberg, , 69115
Serial Number
UK00913365259 filed on 15th Oct 2014
Registration Number
UK00913365259 registered on
13th Mar 2015
Correspondent Address
Chapel Quarter, Mount Street
Nottingham,
NG1 6HQ
Business/management consulting services for employers, in particular consulting services which enable the employer to offer treatment decision support programs as an employee benefit to eligible individuals, namely, in form of offering eligible individuals free-of charge access to cancer treatment decision support programs and services.
Data collection for analytical and clinical purposes, in particular the collection and systematic sorting of specific molecular, genomic and/or clinical data relating to genomic changes, namely, cancer genomic changes, of an individual, namely of a company's employee; providing scientific information through the collection and analysis of genetic information and information regarding the treatment of cancer and other diseases and disorders; data collection for analytical purposes, in particular the collection of mathematical and statistical data, clinical data, genomic data and data of clinical studies relating to the employees' clinical responses to drug treatments and treatment regimes; providing scientific advise in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis and analysis services in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients, in particular genomic data obtained from employees; providing scientific information on employees' genomic changes that contribute to a unique cancer disease; providing research information about drug safety and drug compatibility in relation to cancer therapy and the treatment of individuals, namely employees; scientific consulting services in the fields of pharmaceuticals and genetics, in particular conducting scientific research in drug safety and dosage assessment and drug compatibility studies in the field of cancer treatment therapy for others; electronic storage of medical data and information for physicians and healthcare professionals; providing an on-line, non-downloadable computer platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice.
Providing online databases featuring medical information and diagnostic, prophylactic and therapeutic properties of pharmaceuticals, and genomic information as it relates to medical diagnosis and treatment; pharmaceutical consulting services in pharmaceuticals and genetics in relation to medical treatment options, in particular in the field of clinical diagnostics and therapy, in particular in the field of cancer diagnostics and cancer therapy, namely, medical consulting services in form of treatment decision support services that guide physicians and patients in the use of genetic clinical molecular and efficacy data; medical consulting services in form of providing treatment decision support programs to employers which enable employers and their affiliates to offer disease treatment decision support programs or payment therefor as a service to their employees, family members and/or spouses, namely, in form of an employee benefit to eligible individuals; medical consulting services in form of providing disease treatment decision support services to employees or their treating physicians which enable employers and their affiliates to offer such treatment decision support services or payment therefor as a service to their employees, family members and/or spouses, namely, in form of an employee benefit to eligible individuals; medical consulting services in form of disease treatment decision support services provided by a company or other employer to its employees, namely the provision of state of the art treatment options for diseases, in particular, cancer treatment options, or payment therefor; cancer genomic and molecular medical testing, in particular by using next generation sequencing methods that utilizes the analysis of genomic changes by next generation sequencing of DNA samples provided by and/or derived from individuals participating in the employees' benefit program; collection and analysis of cancer-associated genetic and treatment information, for the purposes of providing medical treatment and diagnosis for individuals, namely employees; services provided by an employer to its employees whereby the employer will offer or make available disease treatment decision support services, such as with respect to cancer, or other diagnostic services, to its employees and/or the employees' respective physicians or other health care providers, or make payment therefor, as an employee benefit.
UK00913365259
Word
Individual